From: The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis
 |  | Dose | Treatment | Harvest | Luminal | Epithelial | Changes in |  |  |
---|---|---|---|---|---|---|---|---|---|
Animal | Compound | (mg/kg per day) | time (days) | time (days) | occlusion (%) | loss (%) | cytokines/GFs | n | Reference |
Rat | Control | - | - | 7 | 0 | <25 | Â | 5 | [46] |
 |  |  |  | 21 | 50–75 | >75 |  | 5 |  |
 | rIL-10 | 10 μg/ml | 0–14 | 7 | 0–<25 | 0–<25 |  | 5 |  |
 |  | at 0.5 μg/h i.p. |  | 21 | 50–75 | >75 |  | 5 |  |
 |  |  | 5–14 | 7 | 0 | 0–<25 |  | 5 |  |
 |  |  |  | 21 | <25 | 50–75 |  | 5 |  |
Rat | Control | - | - | 7 | 0–<25 | 0–<25 |  | 5 | [46] |
 |  |  |  | 21 | 50–75 | >75 |  | 5 |  |
 | Adv-IL-10 | i.m. | 5 | 7 | 0 | 0–25 |  | 6 |  |
 |  |  |  | 21 | <25 | 50–75 |  | 6 |  |
 | Control | i.m. | 5 | 7 | 0 | 0–<25 |  | 6 |  |
 | vector |  |  | 21 | 50–75 | >75 |  | 6 |  |
Rat | CsA | 25 i.m | 2–3 |  |  |  |  |  | [31] |
 |  | + 5 i.m. | 4–27 | 56 | Partial |  |  | 10 |  |
 | CsA | 25 i.m. | 2–3 |  |  |  |  |  |  |
 | + | + 5 i.m. | 4–27 |  |  |  |  |  |  |
 | IL–2 | + 90,000 IU i.p. | 15–19 and 22–26 | 56 | 100 |  |  | 13 |  |
Rat | Control | - | Â | 28 | >75 | >75 | Â | 5 | [37] |
 |  |  |  | 42 | >75 | >75 |  | 5 |  |
 |  |  |  | 56 | n.a. | n.a. |  | 5 |  |
 |  |  |  | 70 | n.a. | n.a. |  | 5 |  |
 | CsA | 25 i.m | 2–3 | 28 | 0 | 0–<25 |  | 5 |  |
 |  | + 5 i.m. | 4–27 | 42 | 0–<25 | <25 |  | 5 |  |
 |  |  |  | 56 | 50–75 | 50–75 |  | 5 |  |
 |  |  |  | 70 | >75 | >75 |  | 5 |  |
 | CsA | 25 i.m. | 2–3 | 28 | 0–<25 | <25 |  | 5 |  |
 | + | +5 i.m. | 4–27 | 42 | 25–50 | 50–75 |  | 5 |  |
 | IL-2 | +300,000 IU i.p. | 15–19 and 22–26 | 56 | 25–50 | 50–75 |  | 5 |  |
 |  |  |  | 70 | >75 | 50–75 |  | 5 |  |
Rat | CsA | 1 s.c. | 0–3 | 3 | 15 | 61 |  | 10 | [60] |
 |  |  | 0–10 | 10 | 18 | 27 |  | 10 |  |
 |  |  | 0–30 | 30 | 86 | 0 |  | 10 |  |
 | CsA | 1 s.c. | 0–30 | 3 | 7 | 18 | TNF-α, IL-2, | 10 |  |
 | + | + | + |  |  |  | PDGF-AA ↓ | 10 |  |
 | human sCR-1 | 20 i.p. | –1 to 7 | 10 | 8 | 26 |  | 10 |  |
 |  |  |  | 30 | 52 | 0 |  | 10 |  |
Rat | Control | - | - | 7 | 30 | 19 | Â | 5 | [49] |
 |  |  | - | 21 | 90 | 100 |  | 5 |  |
 | Control Ab | o.m.p. infusion | 0–7 | 7 | 40 | 23 |  | 5 |  |
 |  |  | 0–14 | 21 | 100 | 100 |  | 5 |  |
 | anti-RANTES Ab | o.m.p. infusion | 0–7 | 7 | 30 | 4 |  | 5 |  |
 |  | 12 μ g/day | 0–14 | 21 | 35 | 84 |  | 5 |  |
Mouse | Control IgG | 200 μg/mouse i.p. | 0, 2, 4, 6 | 35 | 98 |  |  | 7 | [44] |
 | CTLA4 IgG | 200 μg/mouse i.p. | 0, 2, 4, 6 | 35 | 27 |  |  | 7 |  |
 | Control IgG | 200 μg/mouse i.p. | 6, 8, 10, 12 | 35 | 91 |  |  | 4 |  |
 | CTLA4 IgG | 200 μg/mouse i.p. | 6, 8, 10, 12 | 35 | 42 |  |  | 4 |  |